PILOCARPINE HYDROCHLORIDE TABLETS
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
13-10-2020
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
PILOCARPINE HYDROCHLORIDE
Fáanlegur frá:
METHAPHARM INC
ATC númer:
N07AX01
INN (Alþjóðlegt nafn):
PILOCARPINE
Skammtar:
5MG
Lyfjaform:
TABLET
Samsetning:
PILOCARPINE HYDROCHLORIDE 5MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100
Gerð lyfseðils:
Prescription
Lækningarsvæði:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Vörulýsing:
Active ingredient group (AIG) number: 0107358009; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2020-10-14
Vara einkenni
_PILOCARPINE HYDROCHLORIDE TABLETS Product Monograph _
_Page 1 of 33 _
PRODUCT MONOGRAPH
PR
PILOCARPINE HYDROCHLORIDE TABLETS
5 MG
CHOLINOMIMETIC AGENT
Methapharm Inc
81 Sinclair Boulevard
Brantford, Ontario
N3S 7X6, Canada
Date of Revision:
October 13, 2020
Submission Control No.: 241563
_PILOCARPINE HYDROCHLORIDE TABLETS Product Monograph _
_Page 2 of 33 _
Table of Contents
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................11
OVERDOSAGE
................................................................................................................12
ACTION AND CLINICAL PHARMACOLOGY
............................................................13
STORAGE AND STABILITY
..........................................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................18
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL INFORMATION
..........................................................................19
CLINICAL TRIALS
..........................................................................................................20
DETAILED PHARMAC
Lestu allt skjalið
